Children's Hospital Medical Center

Other

University of California

Marc Elliot Rothenberg

Ting Wen

Julie Caldwell

Nurit P Azouz

Philip Leder

Andrew David Luster

Eduardo Garcia

Tetsuo Shoda

Thomas Xuefeng Lu

Nives Zimmermann

Seema S Aceves

Ido Bachelet

John B Harley

Ariel Munitz

Francesca Levi-Schaffer

Leah Kottyan

Carine Blanchard

Yrina Rochman

Mark Rochman

The disclosure provides a simple and rapid blood-based bioassay useful in the diagnosis, treatment and monitoring of eosinophilic gastrointestinal disorders, and related compositions and methods.

Blood biomarker for eosinophilic gastrointestinal disorders

The present invention relates to methods for diagnosing, monitoring, and optionally treating eosinophilic gastritis (EG) and/or eosinophilic gastroenteritis (EGE), the methods comprising assaying one or more tissue, serum, or plasma biomarkers in a biological sample from the subject.

Methods for diagnosing and treating eosinophilic gastritis

Provided are methods for increasing SPINK7 anti-proteinase activity in a target tissue of a subject having an allergic inflammatory condition characterized by inflammation of a squamous epithelium in the target tissue, the method comprising inhibiting kallikrein 5 (KLK5) proteinase activity in the target tissue. Suitable KLK5 inhibitors may include a KLK5-Fc fusion protein, a KLK5 anti-sense polynucleotide, a KLK5-directed miRNA, a KLK5-directed shRNA, a KLK5-directed antibody, or a coumarin compound such as 3-(3-chlorophenyl) carboxy-7-hydroxymethyl coumarin or 3-carboxy-7-hydroxymethyl coumarin.

Compositions and methods for treating allergic inflammatory conditions

The present invention relates to methods for identifying an EoE endotype of a patient and treating the patient with one or more therapies targeted to the patient's disease endotype; and related methods for stratifying patients for clinical trials.

Methods for treating eosinophilic esophagitis

The invention provides methods of treating an allergic inflammatory condition characterized by inflammation of the squamous epithelium of a target tissue by administering to the subject a pharmaceutical composition comprising a kallikrein 5 (KLK5) inhibitor, and a pharmaceutically acceptable carrier.

The invention provides methods of treating an allergic inflammatory condition characterized by inflammation of a squamous epithelium in a target tissue using alpha-1 proteinase inhibitors to replenish SPINK7 protein and/or SPINK7 anti-proteinase activity in the target tissue, and related methods and compositions.

The invention provides (CDH26)-based therapeutic agent, compositions comprising same, and methods of treating inflammatory conditions using same.

Cadherin 26 (CDH26)-Fc fusion proteins and methods of use thereof to treat inflammatory conditions

The invention provides methods for diagnosing eosinophilic esophagitis in a patient using a biomarker based assay directed to KCNJ2/Kir2.1 and related compositions, kits, and computer program products.

Diagnostic method for distinguishing forms of esophageal eosinophilia

Methods and compositions disclosed herein generally relate to determination of susceptibility to eosinophilic esophagitis, asthma, and/or allergic diseases, disorders, and/or pulmonary and/or upper gastrointestinal conditions arising therefrom and/or related thereto and the diagnosis, treatment, and/or management of eosinophilic esophagitis, asthma, and/or allergic diseases, disorders, and/or pulmonary and/or upper gastrointestinal conditions arising therefrom and/or related thereto. Embodiments of the invention relate to the association between genes and specific polymorphisms of genes with eosinophilic esophagitis. Embodiments of the invention can be used to determine and manage patient risk factors for development of eosinophilic esophagitis; this determination can then be used to diagnose eosinophilic esophagitis and to treat a patient diagnosed with eosinophilic esophagitis.

Genetic test for determining susceptibility for eosinophilic esophagitis

A method to evaluate eosinophilic esophagitis based on information in an eosinophilic esophagitis transcriptome.

Evaluation of eosinophilic esophagitis

The disclosure provides methods and compositions for diagnosing a patient eosinophilic esophagitis, the methods based upon the patient's gene expression profile for a panel of genes. The methods can also be used to exclude a diagnosis of chronic esophagitis.

Determination of eosinophilic esophagitis

Embodiments of the invention are directed to methods of diagnosing eosinophilic esophagitis (EoE), or remission therefrom in a subject, wherein the methods include applying a sample from the subject to a diagnostic panel that contains selected markers for EoE, analyzing to obtain relatedness information relative to an EoE cohort and making a determination as to the EoE status of the subject, wherein an analysis indicating grouping with an EoE cohort or a quantitative score similar to that of an EoE cohort are indicative of EoE in the subject. Embodiments of the invention are also directed to methods of monitoring the pathological development or medical prognosis of EoE in a subject.

Diagnostic methods of eosinophilic esophagitis

The disclosure provides compositions and methods related to the diagnosis, prognosis, and treatment of inflammatory diseases and disorders, especially allergic inflammatory diseases and disorders.

Methods of determining eosinophilic gastritis status based on marker or gene expression

Methods and compositions disclosed herein generally relate to methods of treating eosinophilic esophagitis (EE) and eosinophilic disorders by providing or enhancing a diagnosis of EE and eosinophilic disorders. In particular, the invention relates to obtaining a sample from a patient, then quantifying from the sample an amount of one or more microRNAs (miRNAs) associated with EE, wherein an altered level of the miRNA correlates with a positive diagnosis of EE. An EE diagnosis can then be provided or enhanced, based upon the quantifying step, and an appropriate treatment can be administered to the patient. The invention further relates to diagnostic kits, tests, and/or arrays that can be used to quantify the one or more miRNAs associated with EE, as well as treatments developed to up-regulate or down-regulate one or more miRNAs and/or their downstream pathways relevant to EE or asthma. The invention further relates to the use of IGF1 and IGF1R inhibitors for the treatment of EE and eosinophilic disorders.

Esophageal microRNA expression profiles in eosinophilic esophagitis

The invention provides methods of treating allergic inflammatory conditions using an anti-neurotrophin tyrosine kinase receptor 1 (NTRK1)-based therapeutic agent, and related compositions and methods.

Growing community of inventors

Cincinnati, OH, United States of America

Marc Elliot Rothenberg